Thursday, December 04, 2014 9:12:13 AM
full scale 3D liver planned for mid 2016
NOT what he said... but could be confusion caused by his misspeak in the last statement he made: where he talked about the 24 assay per print-tray for liver assays... then said the same thing AGAIN when he likely intended to say "KIDNEY" instead.
BY MID-2016... Organovo is expecting to have available functional kidney assays similar to the liver assays that are now a fully launched commercial product for ONVO.
In the middle of the segment KM talked about the collaboration with Yale on human transplant possibilities... he used words like
longer-term focused collaboration, going to take some time to build larger and larger tissue so that we can think about transplanting full organs, Yale collaboration is geared at solving some of the scientific challenges of building larger organs.
"I call investing the greatest business in the world because you never have to swing... All day you wait for the pitch you like,... The problem when you're a money manager is that your fans keep yelling, 'Swing. you bum!'"
W. Buffett
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
